Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CS19 is a fimbrial colonization factor (CF) expressed by Enterotoxigenic *Escherichia coli* (ETEC), a major bacterial pathogen causing diarrheal illness, particularly in children in developing countries and travelers. This protein mediates the adhesion of ETEC to the host's intestinal epithelial cells, a critical step for establishing infection and subsequent toxin production. CS19 is recognized as a virulence factor and is being investigated as a potential antigen for the development of ETEC vaccines. CS19-expressing ETEC strains are also utilized in human and animal challenge models to study disease pathogenesis and evaluate vaccine candidates.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CS19.